Mass General

Verge is working with four academic institutions to create a broad resource for the translation of preclinical models of amyotrophic lateral sclerosis research.

The newly announced Microbiome Immunity Project seeks to discover links between autoimmune diseases and bacteria in and on the human body.

The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.

The partners aim to develop a diagnostic methodology for obtaining cancer cell molecular profiles to help guide immunotherapies.

The two studies describe methods for identifying off-target mutations associated with cell-type-specific SNPs and detecting potential off-target cleavage sites.

Incorporating splicing and other clues from muscle transcripts, researchers reached diagnoses in cases that were inconclusive after sequencing alone.

Such analyses can help researchers pinpoint how various cancers evolve and determine the best kinds of tests to use to find certain disease information.

Genetic mutations and tumor microenvironment largely account for differences between IDH-A and IDH-O gliomas, the researchers also said.